Research Article
Cancer in ANCA-Associated Glomerulonephritis: A Registry-Based Cohort Study
(a) Standardised incidence ratios for cancers in all sites in the study population |
| Characteristic | Observed | Expected | SIR | 95% CI |
| All | 41 | 37.5 | 1.09 | 0.81 to 1.49 | Non-NMSC | 34 | 35.4 | 0.96 | 0.69 to 1.34 | Sex | | | | | Male | 29 | 22.9 | 1.27 | 0.88 to 1.83 | Female | 12 | 14.6 | 0.82 | 0.47 to 1.44 | Follow-up period | | | | | 0-1 year | 3 | 4.3 | 0.70 | 0.22 to 2.16 | 1–5 years | 22 | 14.4 | 1.53 | 1.01 to 2.32 | 5–10 years | 11 | 11.1 | 0.99 | 0.55 to 1.78 | >10 years | 5 | 7.6 | 0.66 | 0.27 to 1.57 | Transplantation | | | | | Yes | 7 | 3.3 | 2.12 | 1.01 to 4.44 | No | 34 | 34.2 | 0.99 | 0.71 to 1.39 | ANCA serology | | | | | C-ANCA/PR3-ANCA | 24 | 20.6 | 1.17 | 0.78 to 1.74 | P-ANCA/MPO-ANCA | 17 | 16.9 | 1.01 | 0.63 to 1.62 | Study period | | | | | 1988–2002 | 26 | 22.7 | 1.14 | 0.78–1.68 | 2003–2012 | 15 | 14.8 | 1.02 | 0.61–1.68 |
|
|
SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NMSC, nonmelanoma skin cancer; C-ANCA, cytoplasmic ANCA; PR3-ANCA, proteinase 3 ANCA; P-ANCA, perinuclear ANCA; MPO-ANCA, myeloperoxidase ANCA.
|
(b) Standardised incidence ratios for the most common organ-specific cancers in the study population |
| Organs | Observed | Expected | SIR | 95% CI |
| NMSC | 7 | 2.1 | 3.40 | 1.62 to 7.14 | Hematologic | 4 | 1.1 | 3.52 | 1.32 to 9.37 | Lung | 7 | 4.0 | 1.73 | 0.83 to 3.63 | Colon | 2 | 1.2 | 1.73 | 0.43 to 6.93 | Urothelium | 3 | 2.0 | 1.48 | 0.47 to 4.59 | Prostate | 5 | 7.0 | 0.72 | 0.30 to 1.73 | NHL | 1 | 1.2 | 0.86 | 0.12 to 6.12 |
|
|
SIR, standardised incidence ratio; 95% CI, 95% confidence interval; NMSC, nonmelanoma skin cancer; NHL, non-Hodgkin lymphoma.
|